Results 211 to 220 of about 2,823,581 (316)

Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine1 [PDF]

, 2006
Rui Wang, Han Yan, Xi-Can Tang
openalex   +1 more source

Synthetic strategies and medicinal chemistry perspectives of dual acting carbonic anhydrase modulators with monoamine oxidase and cholinesterase inhibitors. [PDF]

RSC Med Chem
Bindra S, Mostafa EM, Abdelgawad MA, Selim S, Kumar S, Mathew B.   +5 more
europepmc   +1 more source

Cholinesterase in marine cockle (<i>Anadara granosa</i> L.): Evidence for the hemolymph cholinesterase activity insensitive to organophosphate inhibitor

, 2002
Janenuj Wongtavatchai, Piyarat Subhachalat, Lila Ruangpan, Jirasak Tangtrongpiros   +3 more
openalex   +2 more sources

Efficient Access to New Thienobenzo-1,2,3-Triazolium Salts as Preferred Dual Cholinesterase Inhibitors. [PDF]

Biomolecules
Mlakić M, Sviben M, Ratković A, Raspudić A, Barić D, Šagud I, Lasić Z, Odak I, Škorić I.   +8 more
europepmc   +1 more source

Cholinesterase Inhibitors for Treatment of Psychotic Symptoms in Alzheimer Disease and Parkinson Disease: A Meta-analysis.

JAMA Neurol, 2023
d'Angremont E, Begemann MJH, van Laar T, Sommer IEC.   +3 more
europepmc   +1 more source

Thyroid function in patients with Alzheimer's disease treated with cholinesterase inhibitors

, 2003
Elisabeth Kapaki, Ιoannis Ilias, George P. Paraskevas, Ioulia Christakopoulou   +3 more
openalex   +2 more sources

A Systematic Review of Practice Guidelines and Recommendations for Discontinuation of Cholinesterase Inhibitors in Dementia.

The American journal of geriatric psychiatry, 2017
B. Renn, A. Asghar-Ali, S. Thielke, Angela Catic, Sharyl R. Martini, B. G. Mitchell, M. Kunik   +6 more
semanticscholar   +1 more source

Barbiturate-sulfonate hybrids as potent cholinesterase inhibitors: design, synthesis and molecular modeling studies. [PDF]

Future Med Chem
Kassem AF, Omar MA, Temirak A, El-Shiekh RA, Srour AM.   +4 more
europepmc   +1 more source

Potential Azo-8-hydroxyquinoline derivatives as multi-target lead candidates for Alzheimer's disease: An in-depth in silico study of monoamine oxidase and cholinesterase inhibitors. [PDF]

PLoS One
Guerguer FZ, Rossafi B, Abchir O, Raouf YS, Albalushi DB, Samadi A, Chtita S.   +6 more
europepmc   +1 more source

Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment

, 2005
Thierry Dantoine, Sophie Auriacombe, Marie Sarazin, H. D. Becker, J.-J. Péré, I. Bourdeix   +5 more
openalex   +1 more source